Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfonso Calvo

Showing results (111-120 of 145) with videos related to

Pageof 15
Sort By:
Frontiers in Immunology|October 16, 2023
A novel [<sup>89</sup>Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancerAnder Puyalto, María Rodríguez-Remírez, Inés López, et al.
Clinical Epigenetics|September 19, 2022
Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancerCora Palanca-Ballester, David Hervas, Maria Villalba, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunityClément Anfray, Francesco Mainini, Elisabeth Digifico, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 20, 2025
Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatmentFlávia Castro, Marta Laranjeiro Pinto, Catarina Leite Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2011
Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistanceMariano Ponz-Sarvisé, Paul A Nguewa, María J Pajares, et al.
Molecular Cancer|April 20, 2024
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulationAnder Puyalto, María Rodríguez-Remírez, Inés López, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 15, 2023
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumorsShubaash Anthiya, Süleyman Can Öztürk, Hamdullah Yanik, et al.
Frontiers in Immunology|January 23, 2024
Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumorsClément Anfray, Carmen Fernández Varela, Aldo Ummarino, et al.
The Journal of Experimental Medicine|September 28, 2022
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicityKarmele Valencia, Mirari Echepare, Álvaro Teijeira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)José María Piulats, Enrique Espinosa, Luis de la Cruz Merino, et al.
Pageof 15

Showing results (111-120 of 145) with videos related to

Sort By:
Pageof 15
Frontiers in Immunology|October 16, 2023
A novel [<sup>89</sup>Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancerAnder Puyalto, María Rodríguez-Remírez, Inés López, et al.
Clinical Epigenetics|September 19, 2022
Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancerCora Palanca-Ballester, David Hervas, Maria Villalba, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunityClément Anfray, Francesco Mainini, Elisabeth Digifico, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 20, 2025
Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatmentFlávia Castro, Marta Laranjeiro Pinto, Catarina Leite Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2011
Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistanceMariano Ponz-Sarvisé, Paul A Nguewa, María J Pajares, et al.
Molecular Cancer|April 20, 2024
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulationAnder Puyalto, María Rodríguez-Remírez, Inés López, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 15, 2023
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumorsShubaash Anthiya, Süleyman Can Öztürk, Hamdullah Yanik, et al.
Frontiers in Immunology|January 23, 2024
Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumorsClément Anfray, Carmen Fernández Varela, Aldo Ummarino, et al.
The Journal of Experimental Medicine|September 28, 2022
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicityKarmele Valencia, Mirari Echepare, Álvaro Teijeira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)José María Piulats, Enrique Espinosa, Luis de la Cruz Merino, et al.
Pageof 15